Study on the appropriate dose of esmketamine for IONM spinal surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059269

Enrollment

Unknown

Registered

2022-04-27

Start date

2022-04-27

Completion date

Unknown

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal surgery

Interventions

one:Intravenous dose of 0.3 mg of esketamine

two:Intravenous injection of the same dose of saline

three:Intravenous dose of 0.1 mg of esketamine

four:Intravenous dose of 0.5mg of esketamine

Eligibility

Sex/Gender

All

Age

10 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing spinal surgery requiring IONM.

Exclusion criteria

Exclusion criteria: 1. Hypertension patients with poor control or without treatment; 2. Patients with hyperthyroidism without treatment or insufficient treatment; 3. Patients with serious cardiovascular diseases (such as myocardial infarction, unstable angina pectoris and congestive heart failure within six months); 4. Patients with elevated intraocular pressure (such as glaucoma); 5. Patients with serious mental diseases; 6. Patients at risk of intracranial hypertension.

Design outcomes

Primary

Measure	Time frame
EEG dual-frequency index;Somatosensory evoked potential;Motion evoked potential;	—

Countries

CHINA

Contacts

Public ContactLin Chunyan

Ningbo NO.6 Hospital

124099908@qq.com+86 18906627090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026